NCT03093116: A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK, ROS, NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must harbor an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement
Exclusions: Symptomatic CNS involvement
https://ClinicalTrials.gov/show/NCT03093116

Comments are closed.

Up ↑